home.aspx
 
EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...

Cenegenics Elite Health

SHARESHARESHARE
Cenegenics® has forged a paradigm shift in medicine, developing a proactive medical approach for optimized health hailed as “next generation medicine” and garnering worldwide media attention. Founded in 1997, Cenegenics is the world's largest age management medicine practice and recognized leading authority in our field. We have 22 centers with others planned. We serve over 20,000 patients globally 2,000 are physicians and their families.
SHARESHARESHARE

RELATED NEWS


Novartis has announced the launch of an innovative technology-based healthcare program called SMS for Life 2.0 in Kaduna State, Nigeria. The program aims to increase the availability of essential medicines and improve care for patients across the region by using simple, available, and affordable technology. SMS for Life 2.0 is a joint public-private partnership led by Novartis and supported by its partners, the Kaduna State Ministry of Health and Vodacom...
WORLDPHARMANEWS.COM
READ MORE

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, including, announced that the US Food and Drug Administration (FDA) has granted a fourth Qualified Infectious Disease Product (QIDP) designation to APX001, the company’s lead antifungal product candidate. The QIDP designation, a provision under the US Generating Antibiotic Incentives Now (GAIN) Act, was approved by Congress in 2012 to offer incentives to companies to bring to market new tr...
PHARMABIZ.COM
READ MORE

Alexion is preparing filings in major markets for its rare disease drug Soliris in a new indication after a positive readout in a rare neurological disease. The Boston biotech enjoys blockbuster revenues thanks to Soliris, which is already approved in three other rare diseases. Approved since 2007 in paroxysmal nocturnal hemoglobinuria (PNH), Soliris is reaching the end of its patent life in the US and EU, where protection ends in 2021 and 2020 respectively.
Rival companies including Amge...


READ MORE

Manufacturing issues have pushed the expected approval of Roche’s experimental drug for multiple sclerosis to next year, bringing to six this year the number of drugs whose approvals by the FDA have been delayed because of questions over production.Tuesday Roche reported the PDUFA date for Ocrevus had been pushed back three months to March 28 from its original Dec. 28, 2016 date. Roche is seeking a license for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PP...
FIERCEPHARMA.COM
READ MORE

Big Data, biology and genomics have led to understanding how to create a new drug from an old one. An algorithm has been used to analyse the molecular properties of an existing drug used for treat some tumors and found that it also works against metabolic syndrome. The research study, published by Nature Communications, was led by the University of Trento. It shows how the approach can help 'drug repositioning', which is a new frontier of pharmacological research that uses new indication...

READ MORE

The US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who have had surgery but still show some evidence of cancer in their lymph nodes. It’s the first time that PD-1 inhibitor Keytruda (pembrolizumab) has been approved in the US for adjuvant use in any cancer, although Merck picked up European approval for this indication in December. Keytruda’s approval in this indication comes on the back of phase III KEYNOTE-054 trial, which sh...

READ MORE

EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...